JAMA Neurol: The treatment of prostate hypertrophic drug tradium may be expected to reduce an individual's risk of Parkinson's disease

FEBRUARY 3, 2021 // -- In a recent study published in the international journal JAMA Neurology, scientists from the University of Iowa and other institutions in the United States, through a large-scale observational study, found that ingesting a special drug to treat prostate hypertrophicity may reduce an individual's risk of Parkinson's disease.
may provide strong evidence that the drug terazosin and similar drugs may potentially prevent or slow the progression of Parkinson's disease.
Photo Source: In the Wikipedia article, researchers analyzed data from nearly 300,000 older men from two large, separate databases, Truven Health Analytics MarketScan in the United States and the National Health Registry in Denmark, to investigate whether the ingestion of the drug tragin was directly related to a reduced risk of Parkinson's disease.
The results, based on previous preclinical studies, showed that travine increased the energy levels of cells in animal models and prevented or slowed the progression of Parkinson's disease. In earlier studies, researchers used data from the Truven database to find that men who took the drug tradium and related drugs had lower levels of signs of disease and a relatively low risk of disease complications.
What's more, the researchers established a good control group in an early database study, tamsulosin, another drug commonly used to treat prostate hypertrophicity, which, unlike tradium, has little effect on cellular energy, and the results show that it is important for the protective effect of tragin.
the latest study also extends previous findings, and the researchers also looked at whether tragin and its associated drugs can boost cell energy production and whether ingesting such drugs can help reduce an individual's risk of Parkinson's disease.
Using databases from the United States and Denmark, the researchers identified 150,000 male individuals who started taking tracozine and similar drugs and matched them to 150,000 male groups who started taking tansorosin based on age and clinical history, explained researcher Jacob Simmering. We also tracked data from these participants to determine exactly how many participants in each group had Parkinson's disease, and in subsequent follow-up studies, male participants who took tragin were 12 to 37 percent more likely to develop Parkinson's disease than those who took tansorosin.
, the researchers also found that long-term use of energy-boosting prostate drugs may increase the duration of the protective effects of the drug.
the researchers concluded that although there were some differences in population and medical architecture between the United States and Denmark, the participants' results showed similar protective effects in both countries.
And the findings, which have been confirmed in a group of international studies, strongly demonstrate that there is a causal link between tragin and similar drugs and the risk of Parkinson's disease, and that future researchers may be able to use the drug tradium to provide neuropharmical protection to populations and to help effectively prevent parkinson's disease if further research, particularly in randomized clinical trials, can confirm this result.
() Original source: Jacob E. Simmering, PhD1; Michael J. Welsh, MD1,2,3,4,5; Lei Liu, PhD6; et al Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease, JAMA Neurol.February 1, 2021. doi:10.1001/jamaneurol.2020.5157